Comparing the current results to its competitors, Brainstorm Cell Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 274.56 %, recorded in the same quarter.
Brainstorm Cell Therapeutics Inc 's Comment on Competition and Industry Peers
The company maintains its competitive position through granted patents, confidential manufacturing expertise, and proprietary research knowledge. Its intellectual property portfolio includes patents licensed from Ramot at Tel Aviv University as well as patents developed and owned by the company. Competitors, including BrainStorm and Ramot at Tel Aviv University, may obtain approval for different products targeting the same indication or for the same product targeting different indications. Competitor products may demonstrate clinical superiority over the company's orphan products. The company's competitive position is influenced in part by coverage and reimbursement decisions from CMS and other payors, with pricing subject to challenge, reduction, or denial. Legislative efforts related to cost containment and price transparency may affect the company's ability to sell its stem cell therapies profitably.
April 11, 2024
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleNEW YORK, April 11, 2024 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, the Company), a leading developer of cellular therapies for neurodegenerative diseases, has recently made a significant achievement by regaining compliance with the NASDAQ Minimum Market Value Rule. This comes as a positive development for the company and highlights its commitment to the advancement of innovative treatments for patients suffering from neurodegenerative diseases.The Notification Letter on Compliance, received by BrainStorm on April 10, 2024, indicates that the company has met the requirement to maintain a minimum market value of $35 m...
Publicly Traded Peers of Brainstorm Cell Therapeutics inc
Aura Biosciences Inc Share Performance
+9.53%
This Quarter
Aura Biosciences Inc
Profile
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.
Cellectis S is a biotechnology company that operates using a business model focused on developing and commercializing gene editing technologies. They utilize a proprietary platform called TALEN® to modify genes for various applications in agriculture, healthcare, and biomanufacturing. By providing innovative solutions through gene editing, Cellectis aims to address critical challenges in these industries and create value for their customers and stakeholders.
Organicell Regenerative Medicine Inc's business model focuses on developing and commercializing regenerative therapies derived from perinatal tissues, such as placental tissues and umbilical cord blood.
Sources:
Brainstorm Cell Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Brainstorm Cell Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
